Is Copanlisib a targeted drug?

Copanlisib is a targeted drug. Targeted drugs are treatments that fight cancer by specifically interfering with specific molecules or signaling pathways inside cancer cells. The main mechanism of copanliside is to target the growth and reproduction of cancer cells by inhibiting phosphatidylinositol 3-kinase (PI3K).

The PI3Ksignaling pathway plays a key role in many malignancies as it promotes the proliferation, survival, and spread of cancer cells. Copanliside is a PI3K inhibitor that can specifically target this signaling pathway, thereby reducing the activity of cancer cells. This specific effect helps minimize damage to normal cells and reduces the common toxic side effects of general chemotherapy drugs.

Copanliside is commonly used to treat relapsed or refractory synovial sarcoma (follicular lymphoma) and diffuse large B-cell lymphoma (diffuse large B-cell lymphoma). Its targeting makes it a promising treatment option, especially when other treatments are ineffective or have failed to control the cancer.

However, just like other drugs, copanlixet may cause some side effects, such as nausea, vomiting, diarrhea, high blood sugar, etc. Therefore, patients need to be monitored closely while using this medication and treated according to the recommendations of their medical professional. In short, copanliside is a targeted drug that specifically combats the growth and spread of cancer cells by inhibiting thePI3Ksignaling pathway.

Copanliside has just been launched in China and has not yet been included in medical insurance. The specific price may not be determined yet. Please consult your local pharmacy for details. There is only the American version of the original drug available abroad, and the price is as high as more than 70,000 yuan.